Compare HPQ & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HPQ | BIIB |
|---|---|---|
| Founded | 1939 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.9B | 24.2B |
| IPO Year | N/A | 1991 |
| Metric | HPQ | BIIB |
|---|---|---|
| Price | $24.37 | $181.70 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 23 |
| Target Price | $25.85 | ★ $176.48 |
| AVG Volume (30 Days) | ★ 13.6M | 2.0M |
| Earning Date | 11-25-2025 | 10-30-2025 |
| Dividend Yield | ★ 4.91% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 2.65 | ★ 10.97 |
| Revenue | ★ $55,295,000,000.00 | $10,065,900,000.00 |
| Revenue This Year | $2.37 | $2.97 |
| Revenue Next Year | $1.71 | N/A |
| P/E Ratio | ★ $9.22 | $16.59 |
| Revenue Growth | 3.24 | ★ 4.77 |
| 52 Week Low | $21.21 | $110.04 |
| 52 Week High | $36.93 | $185.17 |
| Indicator | HPQ | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 43.89 | 80.16 |
| Support Level | $23.50 | $165.75 |
| Resistance Level | $25.05 | $183.93 |
| Average True Range (ATR) | 0.77 | 5.46 |
| MACD | 0.07 | 1.68 |
| Stochastic Oscillator | 48.32 | 89.52 |
HP (formerly Hewlett-Packard) is a behemoth in the PC and printing markets. It has focused on these markets since it exited IT infrastructure in 2015 with the split from Hewlett Packard Enterprise. HP focuses on the commercial market, but maintains sales of consumer devices and printers. The firm has a broad and global customer base, with only one third of sales coming from the US. HP completely outsources manufacturing and relies heavily on channel partners for its sales and marketing.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).